---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030868"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:07:50.232353+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BARDA narrows Vaxart COVID vaccine pact; 5,000-subject follow-up continues

## Summary
- Received Follow-Up Notice on Oct 8: BARDA intends to delimit Project Agreement excluding paused work.
- Approximately 5,000 participants already enrolled in Phase 2b trial will continue to be followed.
- Funding for follow-up of enrolled participants will continue; paused work no longer supported.
- Company believes data from enrolled cohort will provide useful insights to advance COVID program.

## SEC filing metadata
- accession: 0001437749-25-030868
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925030868/0001437749-25-030868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925030868/vxrt20251010_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030868
- JSON: https://secwatch.observer/filing/0001437749-25-030868.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.